Labeler
Janssen Biotech, Inc. NDC Codes
Janssen Biotech, Inc. lists 37 finished drug products in the FDA NDC Directory under NDC labeler code 57894.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Rybrevant Faspro, ustekinumab, Tremfya, Stelara, Imaavy, Lazcluze, Akeega, Talvey, Tecvayli, Zytiga, Simponi, Icotyde, Inlexzo, Carvykti, Darzalex IV
- Active ingredients
- Ustekinumab, Amivantamab, Hyaluronidase (Human recombinant), Abiraterone acetate, Guselkumab, Daratumumab, Golimumab, Nipocalimab, Lazertinib, Niraparib tosylate monohydrate, Talquetamab, Teclistamab
- NDC labeler codes
- 57894
- Strengths
- Abiraterone acetate 500 mg/1; Nipocalimab 185 mg/mL; Ustekinumab 45 mg/.5mL; Ustekinumab 90 mg/mL; Ustekinumab 130 mg/26mL; Daratumumab 100 mg/5mL; Infliximab 100 mg/10mL; Icotrokinra 200 mg/1; Amivantamab 2400 mg/15mL; Hyaluronidase (Human recombinant) 30000 mg/15mL; Amivantamab 3520 mg/22mL; Hyaluronidase (Human recombinant) 44000 mg/22mL; Amivantamab 1600 mg/10mL; Hyaluronidase (Human recombinant) 20000 mg/10mL; Amivantamab 2240 mg/14mL; Hyaluronidase (Human recombinant) 28000 mg/14mL; Gemcitabine 225 mg/1; Guselkumab 200 mg/20mL; Guselkumab 200 mg/2mL; Lazertinib 80 mg/1
- Dosage forms
- Injection, Tablet, Film coated, Injection, Solution, Injection, Solution, Concentrate, Solution, Injection, Powder, Lyophilized, For solution, System, Injection, Suspension, Tablet
- Routes
- Subcutaneous, Intravenous, Oral, Intravesical
- Drug classes (FDA established)
- Interleukin-23 Antagonist, Interleukin-12 Antagonist, Endoglycosidase, Tumor Necrosis Factor Blocker, Cytochrome P450 17A1 Inhibitor, CD38-directed Cytolytic Antibody, Kinase Inhibitor, Poly(ADP-Ribose) Polymerase Inhibitor, Nucleoside Metabolic Inhibitor
- HCPCS / J-code
- J3357 — Injection, ustekinumab, for subcutaneous injection, 1 mg, J9145 — Injection, daratumumab, 10 mg, J1745 — Injection, infliximab, excludes biosimilar, 10 mg
- Package NDCs
- 62
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Icotydeicotrokinra | Icotrokinra 200 mg/1 | Tablet, Film coatedOral | 57894-201 | 57894-0201-0757894-0201-30 | — |
| Rybrevant Fasproamivantamab and hyaluronidase-lpuj (human recombinant) | Amivantamab 2400 mg/15mL; Hyaluronidase (Human recombinant) 30000 mg/15mL | InjectionSubcutaneous | 57894-515 | 57894-0515-01 | — |
| Rybrevant Fasproamivantamab and hyaluronidase-lpuj (human recombinant) | Amivantamab 3520 mg/22mL; Hyaluronidase (Human recombinant) 44000 mg/22mL | InjectionSubcutaneous | 57894-522 | 57894-0522-01 | — |
| Rybrevant Fasproamivantamab and hyaluronidase-lpuj (human recombinant) | Amivantamab 1600 mg/10mL; Hyaluronidase (Human recombinant) 20000 mg/10mL | InjectionSubcutaneous | 57894-510 | 57894-0510-01 | — |
| Rybrevant Fasproamivantamab and hyaluronidase-lpuj (human recombinant) | Amivantamab 2240 mg/14mL; Hyaluronidase (Human recombinant) 28000 mg/14mL | InjectionSubcutaneous | 57894-514 | 57894-0514-01 | — |
| Inlexzogemcitabine intravesical | Gemcitabine 225 mg/1 | SystemIntravesical | 57894-225 | 57894-0225-0157894-0225-99 | — |
| Imaavynipocalimab-aahu | Nipocalimab 185 mg/mL | Injection, Solution, ConcentrateIntravenous | 57894-800 | 57894-0800-01 | — |
| Imaavynipocalimab-aahu | Nipocalimab 185 mg/mL | Injection, Solution, ConcentrateIntravenous | 57894-801 | 57894-0801-01 | — |
| ustekinumab | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | 57894-440 | 57894-0440-0157894-0440-03 | J3357 |
| ustekinumab | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | 57894-441 | 57894-0441-01 | J3357 |
| ustekinumab | Ustekinumab 130 mg/26mL | SolutionIntravenous | 57894-444 | 57894-0444-01 | — |
| Tremfyaguselkumab | Guselkumab 200 mg/20mL | InjectionIntravenous | 57894-650 | 57894-0650-02 | — |
| Tremfyaguselkumab | Guselkumab 200 mg/2mL | InjectionSubcutaneous | 57894-651 | 57894-0651-0257894-0651-0457894-0651-22+1 more | — |
| Lazcluzelazertinib | Lazertinib 80 mg/1 | Tablet, Film coatedOral | 57894-080 | 57894-0080-6057894-0080-90 | — |
| Lazcluzelazertinib | Lazertinib 240 mg/1 | Tablet, Film coatedOral | 57894-240 | 57894-0240-3057894-0240-99 | — |
| Akeeganiraparib tosylate monohydrate and abiraterone acetate | Niraparib tosylate monohydrate 50 mg/1; Abiraterone acetate 500 mg/1 | Tablet, Film coatedOral | 57894-050 | 57894-0050-60 | — |
| Akeeganiraparib tosylate monohydrate and abiraterone acetate | Niraparib tosylate monohydrate 100 mg/1; Abiraterone acetate 500 mg/1 | Tablet, Film coatedOral | 57894-100 | 57894-0100-60 | — |
| Talveytalquetamab | Talquetamab 3 mg/1.5mL | InjectionSubcutaneous | 57894-469 | 57894-0469-01 | — |
| Talveytalquetamab | Talquetamab 40 mg/mL | InjectionSubcutaneous | 57894-470 | 57894-0470-01 | — |
| Tecvayliteclistamab-cqyv | Teclistamab 10 mg/mL | InjectionSubcutaneous | 57894-449 | 57894-0449-01 | — |
| Tecvayliteclistamab-cqyv | Teclistamab 90 mg/mL | InjectionSubcutaneous | 57894-450 | 57894-0450-01 | — |
| Carvykticiltacabtagene autoleucel | Ciltacabtagene autoleucel 100000000 1/1 | Injection, SuspensionIntravenous | 57894-111 | 57894-0111-0157894-0111-02 | — |
| Darzalex IVdaratumumab | Daratumumab 100 mg/5mL | Injection, Solution, ConcentrateIntravenous | 57894-505 | 57894-0505-0557894-0505-20 | J9145 |
| Infliximab | Infliximab 100 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | 57894-160 | 57894-0160-01 | J1745 |
| Rybrevantamivantamab-vmjw | Amivantamab 350 mg/1 | InjectionIntravenous | 57894-501 | 57894-0501-01 | — |
| Darzalex Fasprodaratumumab and hyaluronidase-fihj (human recombinant) | Daratumumab 1800 mg/15mL; Hyaluronidase (Human recombinant) 30000 U/15mL | InjectionSubcutaneous | 57894-503 | 57894-0503-01 | — |
| Tremfyaguselkumab | Guselkumab 100 mg/mL | InjectionSubcutaneous | 57894-640 | 57894-0640-0157894-0640-0457894-0640-06+2 more | — |
| Zytigaabiraterone acetate | Abiraterone acetate 500 mg/1 | Tablet, Film coatedOral | 57894-195 | 57894-0195-0657894-0195-15 | — |
| Stelaraustekinumab | Ustekinumab 130 mg/26mL | SolutionIntravenous | 57894-054 | 57894-0054-1657894-0054-27 | — |
| Darzalexdaratumumab | Daratumumab 100 mg/5mL | Injection, Solution, ConcentrateIntravenous | 57894-502 | — | J9145 |
| Simponi Ariagolimumab | Golimumab 50 mg/4mL | SolutionIntravenous | 57894-350 | 57894-0350-0157894-0350-89 | — |
| Simponigolimumab | Golimumab 100 mg/mL | Injection, SolutionSubcutaneous | 57894-071 | 57894-0071-0157894-0071-0257894-0071-89+1 more | — |
| Zytigaabiraterone acetate | Abiraterone acetate 250 mg/1 | TabletOral | 57894-150 | 57894-0150-12 | — |
| Stelaraustekinumab | Ustekinumab 45 mg/.5mL | Injection, SolutionSubcutaneous | 57894-060 | 57894-0060-0257894-0060-0357894-0060-04 | J3357 |
| Stelaraustekinumab | Ustekinumab 90 mg/mL | Injection, SolutionSubcutaneous | 57894-061 | 57894-0061-0357894-0061-04 | J3357 |
| Simponigolimumab | Golimumab 50 mg/.5mL | Injection, SolutionSubcutaneous | 57894-070 | 57894-0070-0157894-0070-0257894-0070-89+1 more | — |
| Remicadeinfliximab | Infliximab 100 mg/10mL | Injection, Powder, Lyophilized, For solutionIntravenous | 57894-030 | 57894-0030-01 | J1745 |
Janssen Biotech, Inc.: common questions
- What is Janssen Biotech, Inc.'s NDC labeler code?
- 57894. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Janssen Biotech, Inc.?
- Med-Code's HCPCS directory matches J3357, J9145, J1745 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.